By the end of today, an estimated 130 people will have died by suicide in the United States.1 This startling fact highlights our nation’s growing mental health epidemic where:
million
people are struggling with PTSD, anxiety, depression, or OCD.2
of individuals with conditions like schizophrenia, major depressive disorder, bipolar affective disorder, and OCD are treatment resistant3
people battled addiction in 2021,4 more than double the amount in 2019.5
When we formed TARA Mind in 2022, we did so with the belief that our nation’s outdated mental health system – plagued by issues surrounding accessibility, cost, care quality, and treatment efficacy – needed a new approach to address this gargantuan and escalating problem. And so, with a clear mission to tackle health equity barriers that have traditionally prevented individuals struggling with mental health from getting effective care, we set out to build a company that enables access to affordable psychedelic-assisted therapy (PAT).
We are a Public Benefit Corporation whose purpose, by definition and mission, extends beyond profit. TARA Mind was established to have an enduring positive impact on society and the large number of people who are struggling with their mental health. Our approach is rooted in a commitment to safety, science, and sound clinical practice. To meet our ambitious mandate, we are building a values-based system that aligns the interests of multiple stakeholders: Providers, Individuals, and Employers.
Providers
Community
Learning
Operational
Efficiencies
Clients
Educational
Resources on PAT
Trusted
Recommendations
Affordable
Quality Care
Employers
Fewer Disability Claims
& Reduced Medical
Costs for Employers
Higher Productivity
via Reduced Absenteeism
Lower Turnover,
Higher Retention
For an overwhelming number of Americans grappling with mental health conditions, the future feels bleak:
believe that mental health services are inaccessible6
did not receive treatment last year7
can not cover a $1,000 emergency expense8
The TARA Mind Provider Network
To expand access for individuals in need, we are building a network of vetted and highly qualified psychedelic-therapy providers that includes licensed US-based ketamine clinics and trained PAT therapists.
There is a supply-and-demand imbalance between practitioners willing and able to provide quality care and individuals in need of effective mental health support. This is a serious problem where:
55% of psychiatrists & 45% of therapists are not accepting new patients9
Measurement-based Care leads to 75% improvement in remission rates10
But only 18% of psychiatrists and 11% of psychologists in the US leverage symptoms-rating scales to monitor treatment response11